Praxis Precision Medicines, Inc.
PRAX · Nasdaq · United States
Share price · PRAX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PRAX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026+19.9%
- 6 Aug 2026+16.0%
- 4 Jun 2026-5.1%
Nothing announced by PRAX that day or the session before.
- 2 Jun 2026-23.0%
- Day beforeOther material event
- 24 Apr 2026+4.6%
Nothing announced by PRAX that day or the session before.
- 31 Mar 2026+16.5%
Nothing announced by PRAX that day or the session before.
Share of unusual movement by asset
For each asset, the share of PRAX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Relutrigineevents and moves
| 2 | shown from 8 days |
Ulixacaltamideevents and moves
| 2 | shown from 8 days |
Elsunersenevents and moves
| 1 | shown from 8 days |
Vormatrigineevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 78% |
| Other company news (earnings, financing, releases naming no asset) | — | 8% |
| Sessions with no dated event | — | 14% |
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | SCN2A (antisense knockdown)RNA / oligonucleotide | Epilepsy | |
| Phase 3 | Voltage-gated sodium channel (persistent current)Small molecule | EpilepsyDevelopmental and Epileptic Encephalopathies | |
| Phase 3 | T-type calcium channelSmall molecule | Essential Tremor | |
| Phase 3 | Voltage-gated sodium channel (NaV1.2 / NaV1.6)Small molecule | Epilepsy Focal Onset Seizures |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (1)
January 2027 (1)
What to watch
2028 (1)
May 2028 (1)
What to watch
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (20)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $64M | $362M+ $383M short-term inv. | $94M-$82M operating cash flow | report ↗ |
View 19 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $69M | $475M+ $284M short-term inv. | $84M-$78M operating cash flow | report ↗ |
| 2026-Q1 | — | $78M | $537M+ $251M short-term inv. | $93M-$86M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $66M | $150M+ $118M short-term inv. | $74M-$65M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $63M | $158M+ $144M short-term inv. | $71M-$55M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $61M | $166M+ $162M short-term inv. | $69M-$53M operating cash flow | report ↗ |
| 2024-Q4 | — | — | $216M+ $177M short-term inv. | $59M-$56M operating cash flow | report ↗ |
| 2024-Q3 | $0.3M | $42M | $169M+ $188M short-term inv. | $52M-$28M operating cash flow | report ↗ |
| 2024-Q2 | $0.4M | $27M | $146M+ $207M short-term inv. | $33M-$27M operating cash flow | report ↗ |
| 2024-Q1 | $0.4M | $27M | $152M+ $55M short-term inv. | $40M-$21M operating cash flow | report ↗ |
| 2023-Q4 | — | — | $82M+ $0 short-term inv. | $27M-$24M operating cash flow | report ↗ |
| 2023-Q3 | $0.5M | $17M | $102M | $25M-$23M operating cash flow | report ↗ |
| 2023-Q2 | $0.8M | $26M | $125M | $34M-$31M operating cash flow | report ↗ |
| 2023-Q1 | $0.7M | $26M | $81M+ $5.0M short-term inv. | $37M-$33M operating cash flow | report ↗ |
| 2022-Q4 | — | — | $62M+ $39M short-term inv. | $41M-$29M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $30M | $63M+ $61M short-term inv. | $44M-$45M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $44M | $56M+ $109M short-term inv. | $60M-$57M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $53M | $78M+ $133M short-term inv. | $69M-$54M operating cash flow | report ↗ |
| 2021-Q4 | — | — | $140M+ $106M short-term inv. | $59M-$45M operating cash flow | report ↗ |
| 2021-Q3 | — | $33M | $167M+ $112M short-term inv. | $45M-$24M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $267M | $358M+ $242M short-term inv. | $76M-$249M operating cash flow | report ↗ |
Praxis Precision Medicines reported revenue of $0M for fiscal 2025, down 100.0% YoY from $8.55M, with R&D spend of $267.12M, up 75.3% YoY. The company held cash and equivalents of $357.75M and reported a net loss of $303.27M, with quarterly net burn of $303.27M.
The clinical-stage CNS biopharmaceutical company submitted NDAs for ulixacaltamide in essential tremor and relutrigine in SCN2A-DEE and SCN8A-DEE, following positive topline Essential3 and EMBOLD registrational results. It expects POWER1 topline results in Q2 2026, EMBRAVE Part A topline in H1 2026, POWER2 and EMBRAVE3 topline results in 2027, and plans a vormatrigine NDA submission in 2027 if the POWER studies are positive.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $8.6M | $152M | $216M+ $177M short-term inv. | $46M-$132M operating cash flow | report ↗ |
| 2023-FY | $2.5M | $87M | $82M+ $0 short-term inv. | $31M-$111M operating cash flow | report ↗ |
| 2022-FY | $0 | $155M | $62M+ $39M short-term inv. | $54M-$185M operating cash flow | report ↗ |
| 2021-FY | — | $120M | $140M+ $106M short-term inv. | $42M-$125M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 12 sales ($3.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Mastrocola Lauren · Principal Accounting Officer | Award / grant | 72 | $278.91 | $20K | Form 4 |
| 2026-11-13 | Kelly Timothy Edwin · Chief Financial Officer | Award / grant | 3 | $278.91 | $837 | Form 4 |
| 2026-11-13 | Nemiroff Alex · General Counsel and Secretary | Award / grant | 49 | $278.91 | $14K | Form 4 |
| 2026-11-13 | Sniecinski Megan · Chief Operating Officer | Award / grant | 21 | $278.91 | $6K | Form 4 |
| 2026-07-08 | Souza Marcio · director, Chief Executive Officer | Gift | 20,521 | — | — | Form 4 |
| 2026-07-08 | Souza Marcio · director, Chief Executive Officer | Gift | 2,600 | — | — | Form 4 |
| 2026-06-24 | DeSimone Jill · director | Option exercise | 8,566 | $44.25 | $379K | Form 4 |
| 2026-06-24 | DeSimone Jill · director | Option exercise | 3,034 | $147.30 | $447K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 285 reporting institutions held 31.8M shares ($10.0B, 113.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 3,458,863 | $1.1B |
| 2 | Orbis Allan Gray Ltd | 2,472,480 | $796.6M |
| 3 | BlackRock, Inc. | 2,324,929 | $749.1M |
| 4 | FMR LLC | 2,160,943 | $696.2M |
| 5 | PERCEPTIVE ADVISORS LLC | 2,035,986 | $656.0M |
| 6 | BAKER BROS. ADVISORS LP | 1,753,198 | $564.9M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 1,221,944 | $393.7M |
| 8 | DEERFIELD MANAGEMENT COMPANY, L.P. | 963,351 | $310.4M |
| 9 | Driehaus Capital Management LLC | 949,225 | $305.8M |
| 10 | Cormorant Asset Management, LP | 885,500 | $285.3M |
| 11 | STATE STREET CORP | 884,238 | $284.9M |
| 12 | MORGAN STANLEY | 833,491 | $268.5M |
| 13 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 815,739 | $262.8M |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 756,748 | $243.8M |
| 15 | GOLDMAN SACHS GROUP INC | 710,734 | $229.0M |